Wellington Management Group LLP Reduces Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Wellington Management Group LLP cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 22.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 88,591 shares of the specialty pharmaceutical company's stock after selling 26,049 shares during the quarter. Wellington Management Group LLP owned approximately 0.27% of Collegium Pharmaceutical worth $2,538,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after purchasing an additional 175,892 shares during the last quarter. Raymond James Financial Inc. bought a new position in Collegium Pharmaceutical in the fourth quarter valued at $2,432,000. Principal Financial Group Inc. grew its stake in Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Intech Investment Management LLC raised its position in Collegium Pharmaceutical by 593.7% during the fourth quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company's stock worth $1,923,000 after acquiring an additional 57,455 shares in the last quarter. Finally, Barclays PLC increased its position in Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after buying an additional 45,291 shares during the last quarter.

Remove Ads

Analysts Set New Price Targets

A number of research firms have recently weighed in on COLL. Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC restated a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Finally, StockNews.com raised Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $43.60.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now owns 124,421 shares of the company's stock, valued at $3,732,630. This represents a 1.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Colleen Tupper sold 977 shares of the company's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares of the company's stock, valued at $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,693 shares of company stock worth $2,334,994 over the last quarter. 3.98% of the stock is currently owned by insiders.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded up $0.39 on Tuesday, hitting $27.12. The company's stock had a trading volume of 358,999 shares, compared to its average volume of 443,989. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The company has a market capitalization of $871.42 million, a PE ratio of 11.69 and a beta of 0.76. The company has a 50-day simple moving average of $29.06 and a 200 day simple moving average of $31.47.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.